EGFR and neuroendocrine carcinoma: Overall survivals from the start of third-generation EGFR-TKI treatment were 30.8 (95% CI, 3.4–58.2) for patients transformed into SqCC, and 23.8 (95% CI, 21.8–25.8) months for patients transformed into neuroendocrine carcinoma (including SCLC and LCNEC); whereas survivals from the start of rebiopsy were 2.5 months (95% CI, 0.0–10.9) and 6.6 months (95% CI, 4.2–9.0), respectively.